SEC Comment Letter for Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Jun 30, 2022

Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: June 30, 2022 · CIK: 0001006281 · Accession: 0000000000-22-007032

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-33357

Date

June 30, 2022

Author

Eyal Rubin

Form

UPLOAD

Company

Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)

Letter

United States securities and exchange commission logo June 30, 2022 Eyal Rubin Senior Vice President and Chief Financial Officer Protalix BioTherapeutics, Inc. 2 University Plaza, Suite 100 Hackensack, NJ 07601 Re:Protalix BioTherapeutics, Inc. Form 10-K for the Year Ended December 31, 2021 Filed March 31, 2022 File No. 001-33357 Dear Mr. Rubin: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
June 30, 2022
Eyal Rubin
Senior Vice President and Chief Financial Officer
Protalix BioTherapeutics, Inc.
2 University Plaza, Suite 100
Hackensack, NJ 07601
Re:Protalix BioTherapeutics, Inc.
Form 10-K for the Year Ended December 31, 2021
Filed March 31, 2022
File No. 001-33357
Dear Mr. Rubin:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io